DISHMAN

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding outcome of meeting of the Board of Directors of the Company held on March 17, 2017.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 19, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange about the outcome of the board meeting held on February 24, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 22, 2015.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that at the Board Meeting held on July 17, 2015, the board has deffered the agenda pertaining to Approval of Audited Annual Accounts, consequently, the decision of declaration of Dividend has also been deffered.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Outcome of the Board Meeting held on July 17, 2015.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Board has deferred the Agenda relating to approval of the Audited financial statements for the year ended March 31, 2015 in view of disagreement with the statutory auditors with regard to reporting in the consolidated financial statements regarding accounting of employee pension benefits by the Swiss subsidiary CARBOGEN AMCIS, which is covering this liability by participating in an employee retirement benefit plan of a large and well respected insurance company. As per Swiss GAAP, the said subsidiary has no liabil

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding a Outcome of Board Meeting of the Company held on August 13, 2014.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Board of Directors at its meeting held on May 28, 2013 has taken the following the decison : (1) The Board has approved the appointment of whole time Director Mr. Arpit J. Vyas as a Managing Director of the Company with effect from May 28, 2013 and since his present term expires on May 31, 2014, also approved his re-appointment as a Managing Director of the Company for a further period of five years w.e.f. June 01, 2014, subject to approval of the members at their ensuing Annual General Meeting scheduled to be hel

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the Board meeting held on May 25, 2009, among others, the following decisions were taken by the Board of Directors of the Company : 1) Resolution in respect of the Re-appointment of Mr. Janmejay R. Vyas as Managing Director of the Company for a further period of 5 (five) years w.e.f. March 01, 2010 and payment of remuneration to him has been passed, subject to approval of the Members in ensuing Annual General Meeting to be held on July 31, 2009 and also subject to approval of Central Government, if any required. Th

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the Board meeting held on May 22, 2008, among others, the following decisions were taken by the Board of Directors of the Company : The Board has increased the Remuneration of Mrs. Deohooti. J. Vyas, whole-time Director of the Company from Rs. 3.00 lacs to Rs. 5.00 lacs per month w.e.f. 1st June, 2008 upon the recommendation of Remuneration Committee held today i.e. May 22, 2008. The Board has also decided for the payment of Remuneration by way of Commission in terms of the provisions of the Companies Act, 1956, to

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the meeting of the Board of Directors of the company held on October 18,2006, the Board of the company strongly acknowledges the performance of CARBOGEN AMCIS AG, (a research and hi-potent product manufacturing Company as acquired by the company in August, 2006 and whose results are consolidated with the results of the company during the quarter ended September 30,2006) and members of the Board of the company also commended the team of CARBOGEN AMCIS AG for their extra ordinary performance, by passing a specific re

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the Meeting of the Board of Directors of the Company held on July 29, 2005, the Board has discussed inter alia, the followings: 1) Approves the proposal for Acquisition of a contract research company in Switzerland Mr. J.R. Vyas, Managing Director of the Company has been authorised to negotiate and conclude the transaction. 2) Approves the proposal for Joint Venture in Saudi Arabia for production of Glucosamine salts and Mr. J.R. Vyas, Managing Director of the Company has been authorised to negotiate and conclude t

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the board meeting held on March 11,2005 the board approves strategic acquisition of a U.K. based Contract Research Company through its 100% wholly owned subsidiary(WOS) company namely Dishman Europe Ltd., with the authority to the Managing Director Mr.J.R.Vyas to negotiate and finalize the terms of acquisition and execute the necessary documents in this regard.This acquisition will strengthen the business model of Dishman Group.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the meeting of the BOD held on October 28, 2004, the Audit Committee, Remuneration Committee and Shareholders' & Investors' Grievance Committee of the Company, as earlier constituted, have been reconstituted by revision in the composition of members of all the three Committees. The details are as follows : 1) Audit Committee is re-constituted comprising of the following Directors : (i) Mr. Y B Desai, Chairman of the Audit Committee; (ii) Mr. Sanjay Majmudar; (iii) Mr. Ashok C Gandhi; (iv) Mr. Divyabhash C Anjaria.